CN103861003A - Alpinia oxyphylla-radix lindera extract for treating nephropathy and preparation method of extract - Google Patents
Alpinia oxyphylla-radix lindera extract for treating nephropathy and preparation method of extract Download PDFInfo
- Publication number
- CN103861003A CN103861003A CN201410098935.8A CN201410098935A CN103861003A CN 103861003 A CN103861003 A CN 103861003A CN 201410098935 A CN201410098935 A CN 201410098935A CN 103861003 A CN103861003 A CN 103861003A
- Authority
- CN
- China
- Prior art keywords
- extract
- radix linderae
- fructus alpiniae
- alpiniae oxyphyllae
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an alpinia oxyphylla-radix lindera extract for treating nephropathy. The raw materials of the alpinia oxyphylla-radix lindera extract mainly includes the petroleum ether part of an alpinia oxyphylla extract and radix lindera; the alpinia oxyphylla-radix lindera extract mainly comprises alpinia oxyphylla volatile oil and radix lindera volatile oil. The preparation method of the alpinia oxyphylla-radix lindera extract for treating nephropathy comprises steps of alpinia oxyphylla pretreatment, layering treatment, extraction of volatile oil, cleaning of radix lindera tuberous roots, grinding, soaking, extracting through a distillation method, mixing and blending, and packaging. The preparation method of the alpinia oxyphylla-radix lindera extract for treating nephropathy disclosed by the invention can increase concentration of plasma CAMP in blood and is beneficial to phosphorylation of AQP2; and the alpinia oxyphylla-radix lindera extract is important for reduction of urine volume molecules of patients with kidney-yang deficiency and diuresis, is capable of increasing secretion of serum ALD in blood of patients, so as to achieve an effect of reducing urine volume.
Description
Technical field
The technical field that the invention belongs to the plant extract for the treatment of nephropathy, relates in particular to a kind of Fructus Alpiniae Oxyphyllae-Radix Linderae extract for the treatment of nephropathy and preparation method thereof.
Background technology
Fructus Alpiniae Oxyphyllae is the dry mature fruit of Zingiberaceae Alpinia plants Fructus Alpiniae Oxyphyllae Alpiniaoxyphyllamiq., medicinal part is kernel, it is one of Hainan Si great Nan medicine, the compatibility Radix Linderae has warming and recuperating the kidney-YANG, temperatureization kidney qi, reduce the effect of urine amount, be usually used in clinically the seminal emission of kidney qi deficiency and coldness, premature ejaculation, frequent micturition, the diseases such as the enuresis, diabetes spp is in the Chinese medicine category of " quenching one's thirst ", be impairment of the kidney is mainly the development trend of diabetic nephropathy (DN), once there is urine protein, show that the state of an illness is very serious, there is no at present effective treatment means, Fructus Alpiniae Oxyphyllae is as the key component of Pill for Decreasing Urination, play warming and recuperating the kidney-YANG, the effect of temperatureization kidney qi, aldosterone (ALD) is the important substance that regulates body water-electrolyte metabolism, promote body to protect sodium row potassium, maintain the balance of body fluid capacity and osmotic pressure, in close relations with the generation of polyuria, when in blood, ALD concentration reduces, sodium heavily absorbs minimizing, discharge increases, urine increases, when ALD level raises, sodium heavily absorbs and increases, discharge and reduce, urine reduces.For effect and the effective substance thereof of the anti-nephropathy of further clear and definite Fructus Alpiniae Oxyphyllae, Fructus Alpiniae Oxyphyllae is carried out to chemical fraction extraction and effective site screening, to study the mechanism of action of Fructus Alpiniae Oxyphyllae compatibility Radix Linderae the kidney invigorating reducing urination.At present, there is the problem that cannot improve plasma C AMP and serum ALD level, treat nephropathy weak effect in the plant extract of traditional treatment nephropathy and method thereof.
Summary of the invention
The object of the embodiment of the present invention is to provide a kind of Fructus Alpiniae Oxyphyllae-Radix Linderae extract for the treatment of nephropathy and preparation method thereof, is intended to solve the plant extract of traditional treatment nephropathy and method thereof and has the problem that cannot improve plasma C AMP and serum ALD level, treatment nephropathy weak effect.
The embodiment of the present invention is to realize like this, a kind of Fructus Alpiniae Oxyphyllae-Radix Linderae extract for the treatment of nephropathy, this extract raw material composition mainly comprises petroleum ether part and the Radix Linderae (by 1:1) of Fructus Alpiniae Oxyphyllae extract, Fructus Alpiniae Oxyphyllae-Radix Linderae extract mainly comprises Fructus Alpinae Oxyphyllae volatile oil and Radix Linderae volatile oil, described Fructus Alpinae Oxyphyllae volatile oil main component is flower hydrocarbon (55.19%), the blue alkene of refined sill (3.74%), linalool (3.10%), o-pinene (3.06%), γ-terpineol (3.06%), 1.8-cineole (0.90%), described Radix Linderae volatile oil mainly contains Borneolum Syntheticum (borneol), limonene (limonene), β-oxalene (β-humulene) etc.
Further, in the raw material of the Fructus Alpiniae Oxyphyllae-Radix Linderae extract of described treatment nephropathy, Fructus Alpiniae Oxyphyllae is the dry mature fruit of Zingiberaceae Alpinia plants Fructus Alpiniae Oxyphyllae AlpiniaoxyphyllaMiq., and the Radix Linderae is the dried root of canella Radix Linderae Linderaaggregate (Sims) Kosterm.
Treat a preparation method for the Fructus Alpiniae Oxyphyllae-Radix Linderae extract of nephropathy, this preparation method steps flow chart comprises Fructus Alpiniae Oxyphyllae pretreatment, layering processing, extracts volatile oil, cleans Radix Linderae tuber, pulverizing, immersion, way of distillation extraction, mixed preparing, packaging;
Described Fructus Alpiniae Oxyphyllae pretreatment refers to that to utilize pulverizer to carry out processed to Fructus Alpiniae Oxyphyllae fruit powdered, powder is screened with sieves, and the powder sifting out is placed in round-bottomed flask, adds alcohol reflux twice, and each 1h filters with gauze;
Described layering processing refers to and merges the solution that twice filtration obtains, decompression and solvent recovery below 60 DEG C, it is even that extractum adds suitable quantity of water suspendible, uses successively petroleum ether (60~90 DEG C), chloroform, ethyl acetate, n-butanol extraction, and separate each layer in solution;
Described extraction volatile oil refers to the solution of each layer is reduced pressure respectively and reclaims solvent, obtains the extract at each position, takes out the volatile oil of petroleum ether part as the solute of medication, is mixed with containing the stable suspension of 5%Twen-80 for subsequent use;
Described cleaning Radix Linderae tuber refers to block Radix Linderae root is cleaned up, the dry moisture of removing;
Described pulverizing refers to that Radix Linderae tuber is put into pulverizer to be pulverized, and obtains the pulverulent solids of the Radix Linderae;
Described immersion refers to and in pulverulent solids, adds pure water to soak dissolving;
Described way of distillation extraction refers to and utilizes the way of distillation to distill solution, extracts and obtains first Radix Linderae extract, recycles ultrasonic method and carries out second extraction, obtains pure Radix Linderae volatile oil;
Described mixed preparing refers to mixes Fructus Alpinae Oxyphyllae volatile oil and Radix Linderae volatile oil according to the ratio of 1:1, obtain;
Described packaging refers to Fructus Alpiniae Oxyphyllae-Radix Linderae extract is packed in the specification bottle after sterilization according to the specification of every bottle of 100ml, seals.
Further, Fructus Alpiniae Oxyphyllae-Radix Linderae extract in the preparation method of the Fructus Alpiniae Oxyphyllae-Radix Linderae extract of described treatment nephropathy obviously raises (P < 0.05) plasma C AMP content, makes serum ALD content obviously raise (P < 0.01).
The preparation method of the Fructus Alpiniae Oxyphyllae-Radix Linderae extract for the treatment of nephropathy provided by the invention, adopt Fructus Alpiniae Oxyphyllae extract petroleum ether part, can increase the concentration of plasma C AMP in blood, contribute to phosphorylation AQP2, thereby the ability that strengthens transhipment water, the molecule that insufficiency of kidney-YANG polyuria patient is reduced to urine amount has important function; Increase the secretion of serum ALD in patient's blood, thereby played the effect that reduces urine amount; Fructus Alpiniae Oxyphyllae-the Radix Linderae extract for the treatment of nephropathy has improved plasma C AMP and serum ALD level, treatment nephropathy is effective, and preparation method is simple, is easy to promote.
Brief description of the drawings
Fig. 1 is the flow chart of steps of the preparation method of the Fructus Alpiniae Oxyphyllae-Radix Linderae extract of the treatment nephropathy that provides of the embodiment of the present invention.
Detailed description of the invention
In order to make object of the present invention, technical scheme and advantage clearer, below in conjunction with embodiment, the present invention is further elaborated.Should be appreciated that specific embodiment described herein, only in order to explain the present invention, is not intended to limit the present invention.
Below in conjunction with drawings and the specific embodiments, application principle of the present invention is further described.
As shown in Figure 1, a kind of Fructus Alpiniae Oxyphyllae-Radix Linderae extract for the treatment of nephropathy, this extract raw material composition mainly comprises petroleum ether part and the Radix Linderae of Fructus Alpiniae Oxyphyllae extract, Fructus Alpiniae Oxyphyllae-Radix Linderae extract mainly comprises Fructus Alpinae Oxyphyllae volatile oil and Radix Linderae volatile oil, described Fructus Alpinae Oxyphyllae volatile oil main component is flower hydrocarbon (55.19%), the blue alkene of refined sill (3.74%), linalool (3.10%), o-pinene (3.06%), γ-terpineol (3.06%), 1.8-cineole (0.90%), described Radix Linderae volatile oil mainly contains Borneolum Syntheticum (borneol), limonene (limonene), β-oxalene (β-humulene) etc.
Further, in the raw material of the Fructus Alpiniae Oxyphyllae-Radix Linderae extract of described treatment nephropathy, Fructus Alpiniae Oxyphyllae is the dry mature fruit of Zingiberaceae Alpinia plants Fructus Alpiniae Oxyphyllae AlpiniaoxyphyllaMiq., and the Radix Linderae is the dried root of canella Radix Linderae Linderaaggregate (Sims) Kosterm.
Treat a preparation method for the Fructus Alpiniae Oxyphyllae-Radix Linderae extract of nephropathy, this preparation method steps flow chart comprises Fructus Alpiniae Oxyphyllae pretreatment S101, layering treatment S 102, extraction volatile oil S103, cleaning Radix Linderae tuber S104, pulverizes S105, immersion S106, the way of distillation extraction S107, mixed preparing S108, packs S109;
Described Fructus Alpiniae Oxyphyllae pretreatment S101 refers to that to utilize pulverizer to carry out processed to Fructus Alpiniae Oxyphyllae fruit powdered, powder is screened with sieves, and the powder sifting out is placed in round-bottomed flask, adds alcohol reflux twice, and each 1h filters with gauze;
Described layering treatment S 102 refers to and merges the solution that twice filtration obtains, decompression and solvent recovery below 60 DEG C, it is even that extractum adds suitable quantity of water suspendible, uses successively petroleum ether (60~90 DEG C), chloroform, ethyl acetate, n-butanol extraction, and separate each layer in solution;
Described extraction volatile oil S103 refers to the solution of each layer is reduced pressure respectively and reclaims solvent, obtains the extract at each position, takes out the volatile oil of petroleum ether part as the solute of medication, is mixed with containing the stable suspension of 5%Twen-80 for subsequent use;
Described cleaning Radix Linderae tuber S104 refers to block Radix Linderae root is cleaned up, the dry moisture of removing;
Described pulverizing S105 refers to that Radix Linderae tuber is put into pulverizer to be pulverized, and obtains the pulverulent solids of the Radix Linderae;
Described immersion S106 refers to and in pulverulent solids, adds pure water to soak dissolving;
Described way of distillation extraction S107 refers to and utilizes the way of distillation to distill solution, extracts and obtains first Radix Linderae extract, recycles ultrasonic method and carries out second extraction, obtains pure Radix Linderae volatile oil;
Described mixed preparing S108 refers to Fructus Alpinae Oxyphyllae volatile oil and Radix Linderae volatile oil is mixed according to the ratio of 1:1, obtains;
Described packaging S109 refers to Fructus Alpiniae Oxyphyllae-Radix Linderae extract is packed in the specification bottle after sterilization according to the specification of every bottle of 100ml, seals.
Further, Fructus Alpiniae Oxyphyllae-Radix Linderae extract in the preparation method of the Fructus Alpiniae Oxyphyllae-Radix Linderae extract of described treatment nephropathy obviously raises (P < 0.05) plasma C AMP content, makes serum ALD content obviously raise (P < 0.01).
By following experiment, effect of the present invention is described further:
One, " Fructus Alpiniae Oxyphyllae-Radix Linderae " medicine impact on rats with deficiency of kidney-Yang plasma C AMP on extract:
With normal group comparison, insufficiency of kidney-YANG polyuria rat model plasma C AMP content significantly raise (P < 0.01); With model group comparison, irbesartan group raises (P < 0.05) to extract high dose group CAMP content with " Fructus Alpiniae Oxyphyllae-Radix Linderae " medicine, and all the other respectively organize there was no significant difference (P > 0.05), in table 1;
The impact on insufficiency of kidney-YANG polyuria rat plasma CAMP on extract of table 1 " Fructus Alpiniae Oxyphyllae-Radix Linderae " medicine
Two, " Fructus Alpiniae Oxyphyllae-Radix Linderae " medicine impact on insufficiency of kidney-YANG polyuria rat blood serum ALD on extract:
With normal group comparison, insufficiency of kidney-YANG polyuria rat model serum ALD content significantly reduces (P < 0.01); With model group comparison, irbesartan group raises (P < 0.05, P < 0.01) to extract high dose group serum ALD content with " Fructus Alpiniae Oxyphyllae-Radix Linderae " medicine, in table 2;
The impact on insufficiency of kidney-YANG polyuria rat blood serum ALD on extract of table 2 " Fructus Alpiniae Oxyphyllae-Radix Linderae " medicine
Operation principle of the present invention:
As shown in Figure 1, a kind of preparation method steps flow chart of Fructus Alpiniae Oxyphyllae-Radix Linderae extract for the treatment of nephropathy comprises Fructus Alpiniae Oxyphyllae pretreatment S101, layering treatment S 102, extraction volatile oil S103, cleaning Radix Linderae tuber S104, pulverizes S105, immersion S106, the way of distillation extraction S107, mixed preparing S108, packs S109; Described Fructus Alpiniae Oxyphyllae pretreatment S101 refers to that to utilize pulverizer to carry out processed to Fructus Alpiniae Oxyphyllae fruit powdered, powder is screened with sieves, and the powder sifting out is placed in round-bottomed flask, adds alcohol reflux twice, and each 1h filters with gauze; Described layering treatment S 102 refers to and merges the solution that twice filtration obtains, decompression and solvent recovery below 60 DEG C, it is even that extractum adds suitable quantity of water suspendible, uses successively petroleum ether (60~90 DEG C), chloroform, ethyl acetate, n-butanol extraction, and separate each layer in solution; Described extraction volatile oil S103 refers to the solution of each layer is reduced pressure respectively and reclaims solvent, obtains the extract at each position, takes out the volatile oil of petroleum ether part as the solute of medication, is mixed with containing the stable suspension of 5%Twen-80 for subsequent use; Described cleaning Radix Linderae tuber S104 refers to block Radix Linderae root is cleaned up, the dry moisture of removing; Described pulverizing S105 refers to that Radix Linderae tuber is put into pulverizer to be pulverized, and obtains the pulverulent solids of the Radix Linderae; Described immersion S106 refers to and in pulverulent solids, adds pure water to soak dissolving; Described way of distillation extraction S107 refers to and utilizes the way of distillation to distill solution, extracts and obtains first Radix Linderae extract, recycles ultrasonic method and carries out second extraction, obtains pure Radix Linderae volatile oil; Described mixed preparing S108 refers to Fructus Alpinae Oxyphyllae volatile oil and Radix Linderae volatile oil is mixed according to the ratio of 1:1, obtains; Described packaging S109 refers to Fructus Alpiniae Oxyphyllae-Radix Linderae extract is packed in the specification bottle after sterilization according to the specification of every bottle of 100ml, seals.
The foregoing is only preferred embodiment of the present invention, not in order to limit the present invention, all any amendments of doing within the spirit and principles in the present invention, be equal to and replace and improvement etc., within all should being included in protection scope of the present invention.
Claims (4)
1. treat the Fructus Alpiniae Oxyphyllae-Radix Linderae extract of nephropathy for one kind, it is characterized in that, this extract raw material composition mainly comprises petroleum ether part and the Radix Linderae of Fructus Alpiniae Oxyphyllae extract, Fructus Alpiniae Oxyphyllae-Radix Linderae extract comprises Fructus Alpinae Oxyphyllae volatile oil and Radix Linderae volatile oil, described Fructus Alpinae Oxyphyllae volatile oil main component is flower hydrocarbon 55.19%, the blue alkene 3.74% of refined sill, linalool 3.10%, o-pinene 3.06%, γ-terpineol 3.06%, 1.8-cineole 0.90%, and described Radix Linderae volatile oil mainly contains Borneolum Syntheticum, limonene, β-oxalene.
2. Fructus Alpiniae Oxyphyllae-the Radix Linderae extract for the treatment of nephropathy as claimed in claim 1, it is characterized in that, in the raw material of the Fructus Alpiniae Oxyphyllae-Radix Linderae extract of described treatment nephropathy, Fructus Alpiniae Oxyphyllae is the dry mature fruit of Zingiberaceae Alpinia plants Fructus Alpiniae Oxyphyllae, and the Radix Linderae is the dried root of the canella Radix Linderae.
3. treat the preparation method of the Fructus Alpiniae Oxyphyllae-Radix Linderae extract of nephropathy for one kind, it is characterized in that, this preparation method steps flow chart comprises Fructus Alpiniae Oxyphyllae pretreatment, layering processing, extracts volatile oil, cleans Radix Linderae tuber, pulverizing, immersion, way of distillation extraction, mixed preparing, packaging;
Described Fructus Alpiniae Oxyphyllae pretreatment refers to that to utilize pulverizer to carry out processed to Fructus Alpiniae Oxyphyllae fruit powdered, powder is screened with sieves, and the powder sifting out is placed in round-bottomed flask, adds alcohol reflux twice, and each 1h filters with gauze;
Described layering processing refers to and merges the solution that twice filtration obtains, decompression and solvent recovery below 60 DEG C, and it is even that extractum adds suitable quantity of water suspendible, uses successively 60~90 DEG C of petroleum ether, chloroform, ethyl acetate, n-butanol extraction in solution, and separate each layer;
Described extraction volatile oil refers to the solution of each layer is reduced pressure respectively and reclaims solvent, obtains the extract at each position, takes out the volatile oil of petroleum ether part as the solute of medication, is mixed with containing the stable suspension of 5%Twen-80 for subsequent use;
Described cleaning Radix Linderae tuber refers to block Radix Linderae root is cleaned up, the dry moisture of removing;
Described pulverizing refers to that Radix Linderae tuber is put into pulverizer to be pulverized, and obtains the pulverulent solids of the Radix Linderae;
Described immersion refers to and in pulverulent solids, adds pure water to soak dissolving;
Described way of distillation extraction refers to and utilizes the way of distillation to distill solution, extracts and obtains first Radix Linderae extract, recycles ultrasonic method and carries out second extraction, obtains pure Radix Linderae volatile oil;
Described mixed preparing refers to mixes Fructus Alpinae Oxyphyllae volatile oil and Radix Linderae volatile oil according to the ratio of 1:1, obtain;
Described packaging refers to Fructus Alpiniae Oxyphyllae-Radix Linderae extract is packed in the specification bottle after sterilization according to the specification of every bottle of 100ml, seals.
4. the preparation method of the Fructus Alpiniae Oxyphyllae-Radix Linderae extract for the treatment of nephropathy as claimed in claim 3, it is characterized in that, Fructus Alpiniae Oxyphyllae-Radix Linderae extract in the preparation method of the Fructus Alpiniae Oxyphyllae-Radix Linderae extract of described treatment nephropathy obviously raises plasma C AMP content, P < 0.05, serum ALD content is obviously raise, P < 0.01.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410098935.8A CN103861003A (en) | 2014-03-18 | 2014-03-18 | Alpinia oxyphylla-radix lindera extract for treating nephropathy and preparation method of extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410098935.8A CN103861003A (en) | 2014-03-18 | 2014-03-18 | Alpinia oxyphylla-radix lindera extract for treating nephropathy and preparation method of extract |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103861003A true CN103861003A (en) | 2014-06-18 |
Family
ID=50900390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410098935.8A Pending CN103861003A (en) | 2014-03-18 | 2014-03-18 | Alpinia oxyphylla-radix lindera extract for treating nephropathy and preparation method of extract |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103861003A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113416608A (en) * | 2021-06-29 | 2021-09-21 | 中国热带农业科学院热带作物品种资源研究所 | Extraction method of intelligence-developing essential oil for inhibiting listeria monocytogenes and intelligence-developing essential oil |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102284033A (en) * | 2010-06-17 | 2011-12-21 | 苏州知微堂生物科技有限公司 | Preparation technology and production method of integrated novel Suoquan pill dosage form |
CN102861278A (en) * | 2011-07-07 | 2013-01-09 | 中国医学科学院药用植物研究所 | Lipid-lowering extract from effective parts of sharpleaf galangal fruit and preparation and application thereof |
CN103800784A (en) * | 2014-02-12 | 2014-05-21 | 谢毅强 | Fructus alpiniae oxyphyllae and compatible lindera aggregata extract for treating diabetes, and preparation method thereof |
-
2014
- 2014-03-18 CN CN201410098935.8A patent/CN103861003A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102284033A (en) * | 2010-06-17 | 2011-12-21 | 苏州知微堂生物科技有限公司 | Preparation technology and production method of integrated novel Suoquan pill dosage form |
CN102861278A (en) * | 2011-07-07 | 2013-01-09 | 中国医学科学院药用植物研究所 | Lipid-lowering extract from effective parts of sharpleaf galangal fruit and preparation and application thereof |
CN103800784A (en) * | 2014-02-12 | 2014-05-21 | 谢毅强 | Fructus alpiniae oxyphyllae and compatible lindera aggregata extract for treating diabetes, and preparation method thereof |
Non-Patent Citations (4)
Title |
---|
李淑雯: "缩泉丸对醛固酮合成与分泌的调控机制研究", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
王利胜等: "缩泉片中挥发油的提取及其包合物的制备工艺研究", 《中国药业》 * |
石绍淮等: "益智仁不同极性提取物抗老年痴呆作用的研究", 《中国药房》 * |
邱琼华等: "基于尿液生成***探讨缩泉丸配伍机制", 《中国实验方剂学杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113416608A (en) * | 2021-06-29 | 2021-09-21 | 中国热带农业科学院热带作物品种资源研究所 | Extraction method of intelligence-developing essential oil for inhibiting listeria monocytogenes and intelligence-developing essential oil |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104887721A (en) | Ultramicro decoction pieces made of Ganoderma lucidum pure powders, method for preparing ultramicro decoction pieces and application of ultramicro decoction pieces | |
CN1943619B (en) | Method for preparing Chinese medicine origanum volatile oil and its soft capsule | |
CN105853263A (en) | Traditional Chinese medicinal mosquito repelling liquid and preparation method thereof | |
CN105943566A (en) | Preparation method for compound preparation of water-soluble silicon and traditional Chinese medicinal material or edible material extract | |
CN103861003A (en) | Alpinia oxyphylla-radix lindera extract for treating nephropathy and preparation method of extract | |
CN103598590B (en) | Traditional Chinese medicine composition for decreasing blood sugar and application thereof | |
CN101264195A (en) | Compound dragon's blood gel preparations and extraction and preparation technique | |
CN103800784A (en) | Fructus alpiniae oxyphyllae and compatible lindera aggregata extract for treating diabetes, and preparation method thereof | |
CN1813987A (en) | Immunoreaction regulator of eliminating skin and mucous membrane irritability | |
CN104147260B (en) | A kind of ginseng and pilose antler agate card pharmaceutical composition and preparation method thereof | |
CN100350899C (en) | Diphase capsule of red sage root for coronary heart disease and preparation method | |
CN101700385B (en) | Pharmaceutical composition medicinal liquor or tincture for curing white vein disease and preparation method thereof | |
CN1233401C (en) | Agastache capsule for restoring healthy energy andits prepn and application | |
CN106188083B (en) | A method of extracting 1, 8-Cineole volatile oil from folium artemisiae argyi | |
CN102715502B (en) | Preparation method of health food with function of anti-diabetes | |
CN101768537B (en) | Preparation method for medicinal liquor | |
CN105148240A (en) | Medicinal preparation used for treating chronic cardiac failure | |
CN106035915A (en) | Dried coptis deltoidea rhizome health-care tea for preventing diabetes and cardiovascular complications | |
CN109771631B (en) | Agastache rugosus, ginger and jujube composition and preparation method thereof | |
CN100496530C (en) | Traditional Chinese medicinal composition for treating coronary heart disease and its preparation method | |
CN103341044A (en) | Itching-relieving compound preparation and preparation method thereof | |
CN101721448A (en) | Preparation method of silybum marianum total flavonoid as active ingredient of swertia pseudochinensis-silybum marianum liver benefiting product | |
CN113663049B (en) | Li nationality medicine postpartum medicated bath effervescent granules and preparation method thereof | |
CN102669660B (en) | Health-care food with antidiabetic effect | |
CN1315467C (en) | liver-clearing dropping pill for treating hepatitis and its preparing method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140618 |
|
RJ01 | Rejection of invention patent application after publication |